Thrombolytic therapy based on lyophilized platelet-derived nanocarriers for ischemic stroke
Abstract Background Intravenous administration of fibrinolytic drugs, such as recombinant tissue plasminogen activator (rtPA) is the standard treatment of acute thrombotic diseases. However, current fibrinolytics exhibit limited clinical efficacy because of their short plasma half-lives and risk of...
Main Authors: | Martina Migliavacca, Clara Correa-Paz, María Pérez-Mato, Patrick-Brian Bielawski, Issan Zhang, Pauline Marie, Pablo Hervella, Marina Rubio, Dusica Maysinger, Denis Vivien, Pablo del Pino, Beatriz Pelaz, Ester Polo, Francisco Campos |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-01-01
|
Series: | Journal of Nanobiotechnology |
Online Access: | https://doi.org/10.1186/s12951-023-02206-5 |
Similar Items
-
Biomimetic cell-derived nanocarriers in cancer research
by: Enrica Soprano, et al.
Published: (2022-12-01) -
New Approaches in Nanomedicine for Ischemic Stroke
by: Clara Correa-Paz, et al.
Published: (2021-05-01) -
Nutritional and nanotechnological modulators of microglia
by: Dusica Maysinger, et al.
Published: (2016-07-01) -
Thrombolytic Agents: Nanocarriers in Targeted Release
by: Minghua Shen, et al.
Published: (2021-11-01) -
Alkyne-Azide “Click” Chemistry in Designing Nanocarriers for Applications in Biology
by: Pramod K. Avti, et al.
Published: (2013-08-01)